Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through Toll-like receptor 4 signaling

Amanda L. Roberts, Timur A. Mavlyutov, Tanisha E. Perlmutter, Stacy M. Curry, Sherri L. Harris, Anil K. Chauhan & Colleen M. McDowell

Elevated intraocular pressure (IOP) is a major risk factor for the development and progression of primary open angle glaucoma and is due to trabecular meshwork (TM) damage, which leads to impaired aqueous humor outflow. Here, we explore a novel molecular mechanism involved in glaucomatous TM damage. We investigated the role of an endogenous Toll-like receptor 4 (TLR4) ligand, fibronectin-EDA (FN-EDA), in TGFβ2-induced ocular hypertension in mice. We utilized transgenic mouse strains that either constitutively express only FN containing the EDA isoform or contain an EDA-null allele and express only FN lacking EDA, with or without a mutation in Tlr4, in our inducible mouse model of ocular hypertension by injection of Ad5.TGFβ2. IOP was measured over time and eyes accessed by immunohistochemistry for total FN and FN-EDA expression. Constitutively active EDA caused elevated IOP starting at 14 weeks of age. Ad5.TGFβ2 induced ocular hypertension in wildtype C57BL/6J mice and further amplified the IOP in constitutively active EDA mice. TLR4 null and EDA null mice blocked Ad5.TGFβ3-induced ocular hypertension. Total FN and FN-EDA isoform expression increased in response to Ad5.TGFβ2. These data suggest that both TLR4 and FN-EDA contribute to TGFβ2 induced ocular hypertension.

Glaucoma is a heterogeneous group of optic neuropathies with progressive degeneration of the optic nerve leading to vision loss and irreversible blindness. The prevalence of individuals diagnosed with glaucoma worldwide by 2020 is predicted to be over 80 million and by 2040 over 112 million. Glaucoma is characterized by cupping of the optic disc, death of retinal ganglion cells, and optic nerve degeneration. Primary open angle glaucoma (POAG) is the most common form of glaucoma and elevated intraocular pressure (IOP) is the most significant causative risk factor for glaucoma. IOP is the fluid pressure inside the eye that is regulated by the production of aqueous humor in the ciliary body and drainage of aqueous humor by the trabecular meshwork (TM) and uveoscleral outflow. As a result of the aqueous humor primarily passing through the conventional TM outflow pathway, the TM is the major regulator of IOP. The TM is a biomechano-sensitive tissue located at the junction of the iris and cornea. The TM is composed of a series of fenestrated beams and sheets of extracellular matrix (ECM) covered with endothelial-like TM cells. The cribiform region and the inner wall of the Schlemm's canal is the major site of aqueous humor outflow resistance. Overall, the ECM composition of the TM is important in regulating aqueous humor outflow and forming a fluid flow pathway for proper aqueous humor drainage. It is also known that POAG patients have an increased accumulation of ECM proteins within the TM, increased ECM production leads to an increase in aqueous humor (AH) outflow resistance, decreases AH outflow facility, and causes ocular hypertension.

Although the pathology of the disease is well studied, many of the current drug therapies used to lower elevated IOP focus on suppressing the aqueous humor formation and enhancing uveoscleral outflow; however, these particular therapies do not target the molecular pathology of the disease at the TM. Many of these therapies are also not uniformly effective, can progressively lose efficacy, and only slow vision loss progression. Recently, new therapies have begun to target the TM and the underlying pathology such as the Rho kinase/norepinephrine transporter inhibitor netarsudil. However, there is still a need to identify additional novel molecular
mechanisms responsible for glaucomatous damage in which a drug therapy can target the pathology of the disease to lower elevated IOP and prevent further TM damage.

The transforming growth factor beta 2 (TGFβ2) signaling pathway has been well studied in the TM and it is known to be elevated in the aqueous humor and TM tissue of glaucomatous eyes. TGFβ2 has also been shown to mediate fibrosis development and ECM deposition within the TM, and induce ocular hypertension in both mice and in vivo perfusion organ culture systems. We and others have also shown that TGFβ2 signals through the canonical SMAD pathway, alters the ECM in human TM cells, is essential for TGFβ2-induced ocular hypertension in mice, and has the ability to crosstalk with TLR4 signaling.

TGFβ2 signaling increases the production of ECM proteins, including fibronectin (FN). We and others have identified FN, a dimeric multidomain ECM glycoprotein, to be elevated in glaucomatous TM tissues and aqueous humor. FN functions as a regulator of cellular processes, directs and maintains tissue organization and ECM composition, directs ECM-ECM and ECM-cell interactions, and regulates activity of growth factors and proteins associated with ECM remodeling. The multi-domain dimer is composed of type I, type II, and type III domains with over 20 alternatively spliced isoforms. FN is composed of either cellular FN (cFN) or plasma FN (pFN) isoforms. FN has multiple isoforms generated by alternative processing of a single primary transcript at 3 domains: extra domain A (EDA), extra domain B (EDB), and the type III homologies connecting segment. During embryonic development, the fibronectin EDA (FN-EDA) isoform is abundant; however, in adults the presence of FN-EDA is minimal and primarily functions as a structural scaffold and signaling molecule that regulates cell adhesion, proliferation, and migration. In addition, the expression of FN-EDA is upregulated as a response to tissue injury, repair, or remodeling, and during disease states such as epithelial fibrosis, wound healing, and rheumatoid arthritis. Importantly, FN-EDA isoform is elevated in glaucomatous trabecular meshwork tissue compared to normal trabecular meshwork tissue and amplifies the response of TGFβ2 in primary TM cells in culture.

Recently, we discovered that FN-EDA enhances the TGFβ2-induced ECM response in primary TM cells, and this effect can be blocked by inhibition of toll-like receptor 4 (TLR4) signaling. TLR4 is a member of the TLR family of proteins. Historically, TLR4 was first identified as the receptor for lipopolysaccharide (LPS). It is now known that TLR4 can also be activated by damage associated molecular patterns (DAMPs) as a result of tissue damage, cell injury, or ECM remodeling in other diseases. FN-EDA is a known DAMP and activator of TLR4. Our data suggests that TGFβ2 signaling increases ECM production, including production of FN-EDA, leading to activation of TLR4, and increased IOP. Activation of TLR4 downregulates the TGFβ2 antagonist, BMP and activin membrane bound inhibitor (BAMBI), leading to un inhibited TGFβ2 signaling, and a continuation of a pathogenic feed forward loop. These data suggest a TGFβ2-TLR4 signaling crosstalk in the development of glaucomatous TM damage. Here, we identify the importance of FN-EDA in the development of ocular hypertension using transgenic mice that either constitutively express the EDA isoform or contain an EDA null copy, with or without knockdown of Tlr4.

Results
Anterior segment anatomy of transgenic mice. Previously, Chauhan and colleagues generated and characterized several EDA and TLR4 transgenic mouse strains used here: B6.EDA−/− (EDA null), B6.TL4−/− (TLR4 null), B6.EDA+/− (constitutively active EDA), B6.EDA−/−/TLR4−/−, and B6.EDA+/−/TLR4−/−/+. To determine whether there are any gross anatomical changes to the eye of these transgenic mice, we performed a clinical slit-lamp exam comparing each strain to C57BL/6J controls. Both frontal and lateral images were taken of the exterior eye globe at 15, 30, and 60 days post-natal (Supplemental Fig. 1). Irises of all mouse strains at each age group appear densely pigmented with a complex morphology, as previously described for wildtype C57BL/6J mice. The pupils are round, corneas clear, and no obvious clinically observed anterior segment morphometric abnormalities. In addition, histological sections and H&E analysis was performed on the same mice at each time point (Supplemental Fig. 2). The iridocorneal angles are open and TM morphology appears normal for all strains and ages analyzed. Our data suggests that there are no anatomical differences in the anterior segment of the mouse eyes between strains and there are no obvious developmental morphometric abnormalities in B6.EDA−/−, B6.TL4−/−, B6.EDA+/−, B6.EDA−/−/TLR4−/−, or B6.EDA+/−/TLR4−/− mice. We also characterized the TM of each mouse strain at 60 days of age (Fig. 1). All mouse strains showed a defined TM and Schlemm's canal by H&E staining. The TM of all mouse strains stained positive for alpha-SMA, a known protein highly expressed in TM cells, and collagen-1, a known ECM marker in the TM. These data suggest that the TM in all the mouse strains analyzed is present and anatomically normal.

Constitutively active FN-EDA causes elevated IOP in mice. Clinical and histological analysis of the transgenic EDA and TLR4 strains demonstrated normal TM development. However, when comparing baseline IOP readings from each mouse strain (C57BL/6J, B6.EDA−/−, B6.EDA−/−/TLR4−/−, B6.EDA+/−/TLR4−/−, B6.TL4−/−, and B6.EDA+/−) at 5 months of age, IOP in B6.EDA+/− is significantly elevated compared to each of the other strains, including B6.EDA+/−/TLR4−/− (Fig. 2A). These data suggest that EDA can cause elevated IOP and it is TLR4 dependent. To further analyze the effect of EDA on IOP, we measured IOP in C57BL/6J and B6.EDA−/− mice starting at age 8 weeks through 32 weeks of age (Fig. 2B). Significant IOP elevation began at 14 weeks of age in B6.EDA−/− mice compared to C57BL/6J controls and continued through 32 weeks of age. As expected, C57BL/6J mice maintained a normal IOP throughout the 32 weeks as previously reported. These data demonstrate that although the TM develops normally in EDA−/− mice, and EDA+/− mice at 8 weeks of age have a normal IOP, constitutively active EDA causes elevated IOP to develop over time.
FN-EDA and TLR4 are necessary for TGFβ2 induced ocular hypertension. To test the crosstalk between TGFβ2 and TLR4, we utilized our established mouse model of ocular hypertension using Ad5.TGFβ2 virus, which contains a bioactivated form of TGFβ2. Ad5.TGFβ2 was injected intravitreally into one eye of each animal and the contralateral uninjected eye was used as a negative control. In order to determine whether FN-EDA and TLR4 are necessary for Ad5.TGFβ2-induced ocular hypertension phenotype, we tested wildtype C57BL/6J (n = 17), B6.TLR4−/− mice (n = 8), B6.EDA+/+ mice (8), B6.EDA−/− (n = 18), B6.EDA−/−/TLR4−/− (n = 23) and B6.EDA+/+ /TLR4−/− mice. All animals were 60 days old at time of analysis, n = 5 mice/strain. All images taken at 200x magnification.

Figure 1. Histological exam of trabecular meshwork of EDA and TLR4 transgenic mice. (A,D,G,J,M,P) H&E staining of histological sections from C57BL/6J, B6.EDA+/+, B6.TLR4−/−, B6.EDA−/−, B6.EDA+/+,/TLR4−/−, and B6.EDA−/−/TLR4−/− mice. (B, E, H, K, N, Q) Alpha-SMA labeling of the TM in C57BL/6J, B6.EDA+/+, B6.TLR4−/−, B6.EDA−/−, B6.EDA+/+,/TLR4−/−, and B6.EDA−/−/TLR4−/− mice. (C,F,I,L,O,R) Collagen-1 labeling of the TM in C57BL/6J, B6.EDA+/+, B6.TLR4−/−, B6.EDA−/−, B6.EDA+/+,/TLR4−/−, and B6.EDA−/−/TLR4−/− mice. All animals were 60 days old at time of analysis, n = 5 mice/strain. All images taken at 200x magnification.
TGFβ2 increases FN and FN-EDA expression in the trabecular meshwork. Next, we explored the effect of TGFβ2 on FN and FN-EDA expression in the TM of each of the mouse strains (Fig. 4, Supplemental Figs. 3 and 4). Ad5.TGFβ2 significantly increased both FN levels and FN-EDA levels in the TM of C57BL/6J mice (Fig. 4A,D,M,N). B6.EDA+/− mice also expressed the FN-EDA isoform in the TM of uninjected naïve eyes, and TGFβ2 further increased the expression of FN and EDA (Fig. 4B,E,O,P). TGFβ2 had no effect on FN or FN-EDA expression in the TM of B6.TLR4−/− mice, demonstrating again that TLR4 is necessary for TGFβ2-induced TM damage (Fig. 4C,F). Trace amounts of FN and FN-EDA were evident in the TM of B6.EDA−/−, B6.EDA+/− /TLR4−/−, and B6.TL4+/− mice (Fig. 4G,J), but there was no difference between TGFβ2-injected and control eyes. Correlating with the IOP data, TGFβ2 also had no effect on the expression of FN or FN-EDA in the TM of Ad5.TGFβ2-injected and uninjected eyes of B6.EDA−/−, B6.EDA+/− /TLR4−/−, and B6.TL4+/− mice (Fig. 4C,F,H,K,L).

Discussion

Here we identified FN-EDA as a necessary molecule in pathogenic TGFβ2-TLR4 signaling cross-talk in the development of ocular hypertension in mice. Previously we showed that FN containing the EDA isoform can increase ECM production and enhance the effects of TGFβ2 in primary human TM cells in culture, and this effect could be blocked by inhibition of TLR415. We also demonstrated that mutation in Tlr4 blocked TGFβ2-induced ocular hypertension in mice15. We further expanded on this hypothesis here and demonstrated that exclusion of the EDA exon in B6.EDA−/− mice blocked TGFβ2 induced ocular hypertension and constitutive inclusion of the EDA exon in B6.EDA+/+ caused ocular hypertension and further exacerbated the effect of TGFβ2. Importantly, the effect of EDA+/+ on ocular hypertension was dependent on TLR4. These data highlight a novel role of EDA in ocular hypertension and provides a new therapeutic target to lower IOP that is relevant to the pathology of glaucomatous TM damage.

TLR4 is a member of the TLR family of the innate immune system. Recent evidence suggests that endogenous ligands of cell compartments and matrix can activate TLR4, a phenomenon that can occur as a result of tissue damage or extracellular matrix remodeling45–47. These ligands, also known as damage associated molecular patterns (DAMPs), have the potential to cause a cellular response. Endogenous DAMPs include FN-EDA, HMGB-1, and low molecular weight hyaluronic acid amongst others. Here we recapitulate our earlier report that TLR4 is necessary for TGFβ2-induced ocular hypertension15, and further demonstrate FN-EDA is necessary and dependent on TLR4 for TGFβ2-induced ocular hypertension.

TLR4 is a relevant pathway to study in the context of glaucoma. Several polymorphisms have been identified in TLR4 in human SNP studies of glaucoma patients. Shibuya et al identified multiple SNPs (rs10759930, rs1927914, rs1927911, rs12377632, rs2149356, and rs7037117) in the TLR4 gene associated with the risk of normal tension glaucoma (NTG)22. In addition, Takano et al identified in Japanese individuals with POAG, NTG, and exfoliation glaucoma (XFG), the allele frequency of rs2149356 was the most significant. Further, the SNPs at rs10759930, rs1927914, rs1927911, and rs2149356 were all significantly higher in the glaucoma groups compared to the control group33. Navarro-Partida et al evaluated SNPs Asp299Gly (rs4986790 A/G) and Thr399Ile (rs4986791 C/T) in Mexican patients with POAG compared to controls and found that the TLR4 coding SNPs Asp299Gly and Thr399Ile was significantly higher in the POAG patients, suggesting that there is a genetic susceptibility alleles for POAG in the Mexican population34. However, these results may be population specific as another report of a NTG Korean population demonstrated no statistical significance difference between the NTG patients and controls for...
SNPs (rs10759930, rs1927914, rs1927911, rs12377632, rs2149356, rs11536889, rs7037117, and rs7045953) in the TLR4 gene. And, Abu-Amero and colleagues evaluated the SNP at s4986790 in the TLR4 gene of Saudi POAG patients, and found no statistical difference compared to controls. Importantly, the role of TLR4 in fibrogenesis has also been identified and confirmed by specific SNP alleles in TLR4 being associated with a delayed progression of fibrosis in liver disease and conferring an overall protective effect.

Fibronectin is an extracellular glycoprotein that is elevated in the aqueous humor and glaucomatous TM tissues. Fibronectin provides structural support, signaling and regulates growth factors involved in ECM remodeling. Interestingly, fibronectin can bind to itself, other ECM molecules, growth factors, and receptors.
Cellular FN containing the EDA domain has been shown to play important roles in tissue damage and fibrogenesis. Medina et al. showed that human normal TM and glaucomatous TM cells and tissues express the cFN isoforms (EDA and EDB) and that the EDA isoform is elevated in the glaucomatous TM tissue. EDA expression is also induced by TGFβ2 and dexamethasone in primary TM cultures. Here we demonstrate elevated expression of EDA in the mouse TM in response to TGFβ2.

Functionally, it is known that EDA acts as an endogenous ligand for toll-like receptor 4 (TLR4). The activation of TLR4 is also dependent upon the expression of MD-2 and other TLR4 accessory proteins. Recently, α4β1 integrin was identified to function as a TLR4-coreceptor to initiate an EDA-dependent response. In addition, increased EDA levels led to further production of the EDA isoform in dermal fibroblasts. The mechanism in which FN-EDA activates TLR4 in TM cells remains to be identified, but these data support our hypothesis of a progressive feed-forward mechanism of pathogenic TLR4 signaling involving the fibronectin EDA isoform.

EDA null and constitutively active EDA mice with and without mutation of Tlr4 were previously developed and characterized. These transgenic mice provide a means to study the function of the EDA isoform and its dependence on Tlr4 in a controlled strain specific manner using our inducible model of ocular hypertension.

Interestingly, the TM of B6.EDA−/− mice appears to develop normally as shown by gross clinical and histological analysis, and these mice are completely resistant to TGFβ2 induced ocular hypertension. B6.EDA−/− mice also express very little FN in the TM. Previously, it has been shown that depletion of the EDA-domain can lead to a 40% decrease in the remaining FN levels. However, this phenomenon appears to be tissue specific as it is also known that B6.EDA−/− mice have normal levels of FN in the heart and brain. These data highlight that the EDA

Figure 4. TGFβ2 induces FN and FN-EDA expression in C57BL/6J and EDA +/+ mice. All analyses were performed 6-7 weeks post-injection of Ad5.TGFβ2. (A,D) Ad5.TGFβ2 increased both FN and FN-EDA expression in the TM of C57BL/6J mice. (B,E) Ad5.TGFβ2 increased both FN and FN-EDA expression in the TM of B6.EDA+/+ mice. (C,F) Ad5.TGFβ2 had no effect on FN or FN-EDA expression in the TM of B6.TLR4−/− mice. (G,J) Trace amounts of FN-EDA and FN was detected in B6.EDA+/−/TLR4−/− mice, no difference was observed between Ad5.TGFβ2 injected and uninjected eyes. (M,K,L) No detectable FN-EDA expression was observed in B6.EDA−/+ or B6.EDA−/−/TLR4−/− mice, and no difference was observed between Ad5.TGFβ2 injected and uninjected eyes. (O,P) FN and FN-EDA expression quantified by ImageJ analysis for mean intensity/area in the TM of C57BL/6J mice. (Q,P) FN and FN-EDA expression quantified by ImageJ analysis for mean intensity/area in the TM of B6.EDA+/+ mice. C57BL/6J mice (n = 11), B6.EDA+/+ mice (n = 6), B6.TLR4−/− mice (n = 8), B6.EDA−/− (n = 18), B6.EDA−/−/TLR4−/− (n = 22) and B6.EDA+/+/TLR4−/− (n = 16). Statistical significance determined by Student’s paired t-test *P < 0.05.
isoform of FN is necessary for TGFβ32-induced ocular hypertension. Our data also demonstrates that TGFβ32 overexpression in the TM induces expression of both FN as well as expression of the EDA isoform in wildtype C57BL/6J mice and constitutively active EDA+/− mice as measured 7-weeks after TGFβ32 injections, complimenting the increase in IOP in these mice. It is important to note that the anti-cFN-EDA antibody (NBP1-91258; Novus Biologicals) used here is made against the C-terminal region of the Fibronectin protein (within residues 2250–2300). Mouse-anti-FN antibody (clone IST-4; Sigma-Aldrich) recognizes an epitope located within the 5th type III repeat of human plasma fibronectin, which is common to all fibronectin forms. However, the exposure and accessibility of the 5th type III repeat can be affected by unfolding of the FN protein, FN-FN interactions during fibril formation, and placement or interaction within the ECM. Therefore, the binding of this antibody may be affected in certain tissues and disease states and the presence or absence of the EDA domain. This hypothesis is supported by previous studies where both antibodies were used in human TM tissues, and a similar phenotype was noted as we see here, where EDA did not always co-localize with the total FN antibody. Therefore, it is likely that we are underestimating the amount of total FN produced in our experiments.

We also demonstrated that when EDA is constitutively expressed the mice develop high IOP by 14 weeks of age and persists for at least 32 weeks of age. Therefore, constitutively active EDA mice represent a novel mouse model of ocular hypertension. These mice are an excellent resource for the field of ocular hypertension research and TM pathology as they develop ocular hypertension by an early age, maintain open iridocorneal angles, and produce a homogenous response between animals. IOP was also amplified in the TGFβ32 injected eyes of B6.EDA+/− mice compared to the TGFβ32 injected eyes of C57BL6/J mice for 21 days post-injection. Starting at 28 days post-injection the IOP in the TGFβ32 injected eyes of B6.EDA+/− mice lowered to that of the C57BL6/J injected eyes. However, the IOP in the TGFβ32 injected eyes of B6.EDA+/− mice remained significantly elevated compared to their uninjected control eye from day 14 until the end of the time course. These data suggest that there may be an additional compensatory mechanism that is regulating the IOP with the overexpression of both EDA and TGFβ32. We have previously shown a decrease in IOP at around 21 days after Ad5.TGFβ32 injection in other mouse strains which is thought to be due to genetic background differences. Therefore, it could be that the constitutive expression of EDA not only causes elevated IOP and an initial amplification of TGFβ32 responses, but it may also induce a compensatory pathway that can partially reduce the effects. Further analysis of EDA+/− mice and downstream signaling pathways are needed to fully address this phenomenon. A more detailed analysis of the TM over time will help elucidate the exact molecular and pathological changes occurring in the TM that result in the ocular hypertension phenotype. In addition, further characterization will determine whether this TM damage leads to additional glaucomatous phenotypes in the retina ganglion cells and optic nerve of these animals.

In conclusion, we have demonstrated that both Tlr4 and FN-EDA are necessary for TGFβ32-induced ocular hypertension. These data provide a model system to study glaucomatous TM damage and develop novel therapeutic strategies.

Materials and Methods

Animals and Adenovirus Injection. All experiments were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and approved by the University of North Texas Health Science Center (UNTHSC; Fort Worth, TX, USA) and the University of Wisconsin–Madison (Madison, WI) Institutional Animal Care and Use Committee (IACUC) Guidelines and Regulations. The generation of FN-EDA+/−, FN-EDA+/−, FN-EDA+/−/TLR4+/−, and FN-EDA+/−/TLR4+/− mice has previously been described. B6.EDA+/− mice were generated to contain spliced sites at both splicing junctions of the EDA exon and therefore constitutively express only FN containing EDA. B6.EDA−/− mice contain an EDA-null allele of the EDA exon and express only FN lacking EDA. All animals were housed in the UNTHSC vivarium or the UW-Madison vivarium. Adenovirus 5 (Ad5) viral vector expressing human TGFβ3 (Ad5.C226S/C228S) (referred to throughout as Ad5.TGFβ32) (University of Iowa, Iowa City, IA, USA) was used to overexpress TGFβ32 as previously described. Ad5.Null virus (Vector Biolabs, Malvern, PA, USA) was used as a negative control. Briefly, 2 μL of 2.5 × 10^7 plaque-forming units (pfu) was intravitreally injected into one eye, and the uninjected contralateral eyes were used as negative controls as previously described.

Intraocular Pressure Measurements. Intraocular pressure was measured as previously described. Briefly, IOP was measured on isoflurane anesthetized mice using the Tonolab tonometer (Colonial Medical Supply, Franconia, NH, USA). All IOP measurements were performed during the same time period of the light-on phase. Statistical significance was determined by one-way ANOVA followed by Tukey analysis at each time point, comparing the injected eyes and contralateral uninjected eyes between each strain. All mice were at least 5 months old for adenoviral injection experiments.

Immunohistochemistry of Mouse Eyes. After completion of the IOP time course after Ad5.TGFβ32 injection, mouse eyes were enucleated and fixed in 4% PFA overnight. Eyes were embedded in paraffin, cut into 5-μm sections, and transferred to glass slides. Slides were heated for 2 hours on a heated plate. Deparaffinization was performed by washing with xylene, 100% ethanol, and 95% ethanol, twice for 2 minutes each. Slides were soaked in distilled water and antigen retrieval (citrate buffer) was performed in 65°C water bath for 30 minutes. Tissues were cooled off to room temperature and washed with 1X PBS three times. Tissues were stained with hematoxylin and eosin or blocked using Superblock Blocking Buffer in PBS (Thermo Fisher Scientific) for 60 minutes and further processed for immunohistochemistry as follows. For TM morphology analysis, primary rabbit-anti-smooth muscle actin (1:100, ab5694, Abcam) and rabbit-anti-collagen-1 (1:100, ab34710, Abcam) were used followed by secondary antibody Alexa Fluor-labeled Donkey-anti Rabbit Ig (ThermoFisher), 1:500 dilution. For FN analysis, primary rabbit-anti–cFN-EDA antibody (1:100, NBP1-91258; Novus Biologicals) and mouse-anti-FN antibody (1:100, clone IST-4; Sigma-Aldrich) were used followed by secondary antibodies Alexa Fluor-labeled anti-rabbit
Ig (Life Technologies) 1:500 dilution and Alexa Fluor-labeled donkey anti-mouse Ig (Life Technologies) 1:500. The mouse–anti-FN antibody recognizes epitopes on the N-terminus of FN, which are expressed by all FN isoforms. Slides were mounted with Prolong Gold mounting medium containing DAPI (Invitrogen–Molecular Probes). Images were taken using Keyence microscope BZ-XY10 (Itasca, IL) or Zeiss Axio Imager Z2 microscope. All images were taken at ×200 magnification. Mean florescence intensity/area was measured in a masked manner for each image using ImageJ. Statistical significance was determined by Student’s paired t-test for each animal comparing the TGF-β2-injected eye to the contralateral uninjected eye.

Slit-lamp examination. Anterior segment phenotypes were assessed with a slit-lamp (SL-D7; Topcon, Tokyo, Japan) and photo documented with a digital camera (D100; Nikon, Tokyo, Japan). Images were taken with identical camera settings and prepared with identical image software processing.

Data availability
All data generated or analyzed during this study are included in this published article.

Received: 29 October 2019; Accepted: 27 May 2020;
Published online: 17 June 2020

References
1. Quigley, H. A. Open-angle glaucoma. N Engl J Med 328, 1097–1106, https://doi.org/10.1056/NEJM199304153281507 (1993).
2. Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121, 2081–2090, https://doi.org/10.1016/j.ophtha.2013.10.053 (2014).
3. Landesberg, J. Primary glaucoma: open-angle type; an experimental investigation on a new therapeutic approach in the treatment of simple chronic glaucoma. American journal of ophthalmology 48, 81–85 (1959).
4. Kass, M. A. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of ophthalmology (Chicago, Ill.: 1960) 120, 701–713, https://doi.org/10.1001/archophtha.120.6.701 (2002).
5. Henderson, E. E. & Starling, E. H. The influence of intra-ocular pressure on the rate of drainage of aqueous humour; stabilization of intra-ocular pressure or of aqueous flow? The British journal of ophthalmology 31, 160–176 (1947).
6. Vranka, J. A., Kelley, M. J., Acott, T. S. & Keller, K. E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental eye research 133, 112–125, https://doi.org/10.1016/j.exer.2014.07.014 (2015).
7. Hogän, M. I., Alvarado, J., Weddep, J. & Hilding, E. Histology of the Human Eye: an Atlas and Textbook. (Saunders, 1971).
8. Gong, H., Tripathi, R. C. & Tripathi, B. J. Morphology of the aqueous outflow pathway. Microscopy research and technique 33, 336–367, 10.1002/(SICI)1097-0029(19960303)33:4<336::AID-JEMT>3.0.CO;2-N (1996).
9. Taniguchi, T. & Kitazawa, Y. A risk-benefit assessment of drugs used in the management of glaucoma. Drug safety 47, 622–628, https://doi.org/10.1007/s11044-007-9137-5 (2006).
10. Thompson, A. J. et al. Human trabecular meshwork and Induction by Transforming Growth Factor-beta2. Investigative ophthalmology & visual science 49, 622–628, https://doi.org/10.1167/iovs.08-2558 (2008).
11. Medina-Ortiz, W. E., Belmares, R., Neubauer, S., Wordinger, R. J. & Clarks, A. F. Cellular Fibronectin Expression in Human Trabecular Meshwork and Induction by Transforming Growth Factor-beta2. Investigative ophthalmology & visual science 54, 6779–6788, https://doi.org/10.1167/iovs.13-12298 (2013).
12. Hernandez, H., Millar, J. C., Curry, S. M., Clarks, A. F. & McDowells, C. M. BMP and Activin Membrane Bound Inhibitor Regulates the Extracellular Matrix in the Trabecular Meshwork. Investigative ophthalmology & visual science 59, 2154–2166, https://doi.org/10.1167/iovs.13-12298 (2013).
13. Pang, J. H., Millar, J. C. & Clarks, A. F. Extracellular Matrix in the Trabecular Meshwork. Experimental eye research 141, 33–41, https://doi.org/10.1016/j.exer.2015.04.003 (2015).
14. Hernandez, H., Medina-Ortiz, W. E., Luan, T., Clarks, A. F. & McDowells, C. M. Crosstalk Between Transforming Growth Factor-beta2 and Toll-Like Receptor 4 in the Trabecular Meshwork. Investigative ophthalmology & visual science 58, 1811–1823, https://doi.org/10.1167/iovs.16-21331 (2017).
15. Wordinger, R. J., Sharma, T. C. & Clarks, A. F. The role of TGF-beta2 and bone morphogeneic proteins in the trabecular meshwork and glaucoma. Journal of ophthalmology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 30, 154–162, https://doi.org/10.1155/2013/2020 (2014).
16. Tam, E. R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 88, 648–655, https://doi.org/10.1016/j.exer.2009.02.007 (2009).
17. Acott, T. S. & Kelley, M. J. Extracellular matrix in the trabecular meshwork. Exp Eye Res 86, 543–561, https://doi.org/10.1016/j.exer.2008.01.013 (2008).
18. McDowells, C. M., Hernandez, H., Mao, W. & Clarks, A. F. Gremlin Induces Ocular Hypertension in Mice Through Smad3-Dependent Signaling. Investigative ophthalmology & visual science 56, 5485–5492, https://doi.org/10.1167/iovs.15-16993 (2015).
19. Sharmas, T. P., Currys, M. R. & McDowells, C. M. Effects of Toll-Like Receptor 4 Inhibition on Transforming Growth Factor-beta2 Signaling in the Human Trabecular Meshwork. J Ocul Pharmacol Ther 30, 170–178, https://doi.org/10.1089/jop.2019.0076 (2020).
20. Taniguchi, T. & Kitazawa, Y. A risk-benefit assessment of drugs used in the management of glaucoma. Drug safety 11, 68–74, https://doi.org/10.1215/00020198194110100606 (1994).
21. Lin, C. W. et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther 34, 40–51, https://doi.org/10.1089/jop.2017.0023 (2018).
22. Inatani, M. et al. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefe’s Arch Clin Exp Ophthalmol 239, 109–113 (2001).
23. Ochiai, Y. & Ochiai, H. Higher concentration of transforming growth factor-beta 2 in aqueous humor of glaucomatous eyes and diabetic eyes. Invest Ophthalmol Vis Sci 46, 249–253 doi:S001161860052339 (2002).
24. Ozcan, A. A., Ozdemir, N. C. & Canataro, A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int Ophthalmol 25, 19–22 (2004).
25. Tripathi, R. C., Li, I., Chan, W. F. & Tripathi, B. J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 59, 723–727 doi:S001161860052339 (2001).
26. Plenm, D. L. et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Investigative ophthalmology & visual science 47, 226–234, https://doi.org/10.1167/iovs.05-0160 (2006).
28. Wordinger, R. J. et al. Effects of TGF-beta, BMP-4, and gelatin in the trabecular meshwork: implications for glaucoma. *Investigative ophthalmology & visual science* **48**, 1191–1200, https://doi.org/10.1167/iovs.06-0926 (2007).

29. Tovar-Vidalés, T., Clark, A. F. & Wordinger, R. J. Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. *Experimental eye research* **93**, 442–451, https://doi.org/10.1016/j.exer.2011.06.011 (2011).

30. Sethi, A., Jain, A., Zode, G. S., Wordinger, R. J. & Clark, A. F. Role of TGFBeta/Smad signaling in glaucoma induction of human trabecular meshwork extracellular matrix proteins. *Investigative ophthalmology & visual science* **52**, 5251–5259, https://doi.org/10.1167/iovs.11-7587 (2011).

31. Zode, G. S. et al. Transforming growth factor-beta2 increases extracellular matrix proteins in optic nerve head cells via activation of the Smad signaling pathway. *Mol Vis* **17**, 1745–1758 doi:102 (2011).

32. Javelaud, D. & Mauviel, A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. *Oncogene* **24**, 5742–5750, https://doi.org/10.1080/01656140500322553 (2005).

33. Javelaud, D. & Mauviel, A. Transforming growth factor-betas: smad signaling and roles in physiopathology. *Pathol Biol (Paris)* **52**, 50–54, https://doi.org/10.1016/j.pathbio.2003.10.002 (2004).

34. Javelaud, D. & Mauviel, A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. *Int J Biochem Cell Biol* **36**, 1161–1165, https://doi.org/10.1016/j.biocel.2003.03.005 (2004).

35. Massague, J. & Chen, Y. G. Controlling TGF-beta signaling. *Dev Cell* **14**, 627–644 (2000).

36. Abu-Amero, K. K. et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. *Investigative ophthalmology & visual science* **58**, 689–693, https://doi.org/10.1167/iovs.08-2051 (2009).

37. Jarnagin, W. R., Rockey, D. C., Koteliansky, V. E., Wang, S. S. & Bissell, D. M. Expression of variant fibronectins in wound healing: maintaining and amplifying fibrosis in scleroderma. *Invest Ophthalmol Vis Sci* **57**, 400–408, https://doi.org/10.1167/iovs.11-7587 (2011).

38. Ffrench-Constant, C. Alternative splicing of fibronectin—many different proteins but few different functions. *Mol Vis* **16**, 1–14, https://doi.org/10.1002/mcb.20388 (2008).

39. Serini, G. et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta. *J Cell Biol* **142**, 873–881, https://doi.org/10.1083/jcb.142.5.873 (1998).

40. Muro, A. F. et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. *J Cell Biol* **162**, 149–160, https://doi.org/10.1083/jcb.200212079 (2003).

41. Kuhn, C. et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. *The American review of respiratory disease* **140**, 1693–1703, https://doi.org/10.1164/ajrccm/140.6.1693 (1989).

42. French-Constant, C., Van de Water, L., Dvorak, H. F. & Hynes, R. O. Regulation of fibronectin splicing during wound healing in the adult rat. *J Cell Biol* **119**, 903–914, https://doi.org/10.1083/jcb.109.2.903 (1999).

43. Hino, K. et al. EDA-containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells. *Arthritis Rheum* **38**, 678–683 (1995).

44. Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. *Am J Pathol* **182**, 192–205, https://doi.org/10.1016/j.ajpath.2012.09.0075002-9440.012007-01 (2013).

45. Guo, J. & Friedman, S. L. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. *Fibrogenesis Tissue Repair* **3**, 21, https://doi.org/10.1186/1755-1356-3-211755-1356-3-21 (2010).

46. Yang, L. & Seki, E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. *Front Physiol* **3**, 138, https://doi.org/10.3389/fphys.2012.00138 (2012).

47. Okamura, Y. et al. The extra domain A of fibronectin activates Toll-like receptor 4. *J Biol Chem* **276**, 10229–10233, https://doi.org/10.1074/jbc.M100099200 (2001).

48. Prakash, P., Kulkarni, P. P., Lenzt, S. R. & Chauhan, A. K. Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet-Toll-like receptor 4. *Blood* **125**, 3164–3172, https://doi.org/10.1182/blood-2014-10-608655 (2015).

49. Anderson, M. G., Hawes, N. L., Trantow, C. M., Chang, B. & John, S. W. Iris phenotypes and pigment dispersion caused by genes maintaining and amplifying fibrosis. *Invest Ophthalmol Vis Sci* **135**, 30756–30763 (1999).

50. Wordinger, R. J. et al. Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. *Ophthalmology & visual science* **156**, 115–124 (2000).

51. Navarro-Partida, J. et al. Association of Toll-like receptor 4 gene single-nucleotide polymorphisms A399G and Th399Ile with the risk of primary open angle glaucoma. *Graefes Arch Clin Exp Ophthalmol* **255**, 995–1001, https://doi.org/10.1007/s00417-017-3610-4 (2017).

52. Wordinger, R. J. et al. EDA-fibronectin in injured human skin fibroblast and its potential application in estimation of wound healing. *Fa Yi Xue Za Zhi* **23**, 94–96 (2007).
66. Medina-Ortiz, W. E., Belmares, R., Neubauer, S., Wordinger, R. J. & Clark, A. F. Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-β. IOVS 54, 6779–6788 10.1167/iovs.13-12298 (2013).

67. Filla, M. S., Dimeo, K. D., Tong, T. & Peters, D. M. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Experimental eye research 165, 7–19, https://doi.org/10.1016/j.exer.2017.08.017 (2017).

68. Yang, H., Young, D. W., Gusovsky, F. & Chow, J. C. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 275, 20861–20866, https://doi.org/10.1074/jbc.M002896200 (2000).

69. Kelsh-Lasher, R. M., Ambesi, A., Bertram, C. & McKeown-Longo, P. J. Integrin alpha4beta1 and TLR4 Cooperate to Induce Fibrotic Gene Expression in Response to Fibroinectin's EDA Domain. J Invest Dermatol 137, 2305–2512, https://doi.org/10.1016/j.jid.2017.08.005 (2017).

70. Cseh, B. et al. Autocrine fibronectin directs matrix assembly and crosstalk between cell-matrix and cell-cell adhesion in vascular endothelial cells. J Cell Sci 123, 3989–3999, https://doi.org/10.1242/jcs.073346 (2010).

71. Hocking, D. C., Smith, R. K. & McKeown-Longo, P. J. A novel role for the integrin-binding III-10 module in fibronectin matrix assembly. J Cell Biol 133, 431–444, https://doi.org/10.1083/jcb.133.2.431 (1996).

72. Hocking, D. C., Sottile, J. & McKeown-Longo, P. J. Fibronectin's III-1 module contains a conformation-dependent binding site for the amino-terminal region of fibronectin. J Biol Chem 269, 19183–19187 (1994).

73. Maqueda, A., Moyano, J. V., Hernandez Del Cerro, M., Peters, D. M. & Garcia-Pardo, A. The heparin III-binding domain of fibronectin's III4-5 repeats binds to fibronectin and inhibits fibronectin matrix assembly. Matrix Biol 26, 642–651, https://doi.org/10.1016/j.matbio.2007.06.001 (2007).

Acknowledgements
National Institute of Health R01EY02652 (CMM), National Institute of Health R01EY026529 R01 Diversity Supplement (CMM, ALR), National Institute of Health R25GM125587 (ALR), Unrestricted grant from Research to Prevent Blindness, Inc. to the UW Madison Department of Ophthalmology and Visual Sciences, National Institute of Health R35HL139926, RO1NS109910 and U01NS113388 (AKC), Established Investigator Award (18EIA33900009) from American Heart Association (AKC). This study was supported in part by the Core Grant for Vision Research from the National Institute of Health to the University of Wisconsin-Madison (P30 EY016665).

Author contributions
A.L.R. and C.M.M. designed the study and wrote the manuscript. A.L.R., C.M.M., T.A.M., T.E.P., S.M.C., S.L.H. conducted the experiments and the data analysis. A.K.C. generated the transgenic mice and reviewed and edited the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66756-6.

Correspondence and requests for materials should be addressed to C.M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020